Literature DB >> 7341284

Sotalol and metoprolol comparison of their anti-hypertensive effect.

O Andersson, G Berglund, R Descamps, J Thomis.   

Abstract

28 patients, aged 35-62 years, with uncomplicated hypertension, entered a double-blind, crossover study, in which the effects of single daily doses of sotalol and metoprolol were compared. Both drugs exerted a clinically useful anti-hypertensive effect as monotherapy, or in combination with a thiazide diuretic. No significant difference in hypotensive effects was noted between the two beta-blocking agents, when the dose was titrated to an optimal clinical effect. Treatment with sotalol and metoprolol was associated with a clinically insignificant increase in serum uric acid concentration. The side-effects observed were few, and in only two cases was therapy discontinued. We regard both sotalol and metoprolol as useful anti-hypertensive drugs.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7341284     DOI: 10.1007/bf00637506

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

1.  Comparison of effects of metoprolol and propranolol on asthmatic airway obstruction.

Authors:  C Skinner; J Gaddie; K N Palmer
Journal:  Br Med J       Date:  1976-02-28

2.  Beta-blockers: once or three times a day?

Authors:  T Reybrouck; A Amery; R Fagard; P Jousten; P Lijnen; E Meulepas
Journal:  Br Med J       Date:  1978-05-27

3.  Antihypertensive effects of practolol and sotalol.

Authors:  H Sundquist; M Anttila; M Arstila
Journal:  Clin Pharmacol Ther       Date:  1974-09       Impact factor: 6.875

4.  Long-term effect of alprenolol as antihypertensive agent.

Authors:  C Bengtsson
Journal:  Acta Med Scand Suppl       Date:  1974

5.  Separation and spectrofluorometric assay of the -adrenergic blocker sotalol from blood and urine.

Authors:  E R Garrett; K Schnelle
Journal:  J Pharm Sci       Date:  1971-06       Impact factor: 3.534

6.  Antihypertensive effect of sotalol and propranolol a double-blind crossover study.

Authors:  G Berglund
Journal:  Curr Ther Res Clin Exp       Date:  1977-01

7.  Organization and efficacy of an out-patient hypertension clinic.

Authors:  O Anderson; G Berglund; L Hansson; R Sannerstedt; R Sivertsson; J Wikstrand; L Wilhelmsen
Journal:  Acta Med Scand       Date:  1978

8.  Atenolol in essential hypertension.

Authors:  M G Myers; G R Lewis; J Steiner; C T Dollery
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

9.  Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. II. Relationship to its effect on blood pressure and plasma renin activity.

Authors:  P Collste; K Haglund; M Frisk-Holmberg; M L Orme; M D Rawlins; J Ostman
Journal:  Eur J Clin Pharmacol       Date:  1976-06-15       Impact factor: 2.953

10.  Comparative study of metoprolol and alpha-methyldopa in untreated essential hypertension.

Authors:  R H Bergstrand; J A Vedin; C E Wilhelmsson; G Berglund
Journal:  Eur J Clin Pharmacol       Date:  1976       Impact factor: 2.953

View more
  4 in total

Review 1.  Metoprolol: a pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy.

Authors:  D H Peters; P Benfield
Journal:  Pharmacoeconomics       Date:  1994-10       Impact factor: 4.981

Review 2.  Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  B N Singh; P Deedwania; K Nademanee; A Ward; E M Sorkin
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

Review 3.  Lowering and Raising Serum Urate Levels: Off-Label Effects of Commonly Used Medications.

Authors:  Nicole Leung; Kevin Yip; Michael H Pillinger; Michael Toprover
Journal:  Mayo Clin Proc       Date:  2022-07       Impact factor: 11.104

Review 4.  Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.

Authors:  P Benfield; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1986-05       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.